Skip to content

Side by side

Semaglutide vs SLU-PP-332

Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.

Semaglutide and SLU-PP-332 compared on what BioAlmanac records.
 SemaglutideSLU-PP-332
What it isA long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.A mouse compound that got a press release. It reproduced some effects of endurance training in mice, and no human has ever taken it.
EvidenceHow much human evidence exists, not how well it works.ApprovedPreclinical
Regulatory statusReviewed 2026-08-12Approved by the FDA as a prescription medicine for type 2 diabetes and for chronic weight management. Material sold as a research chemical is not the approved product — is not manufactured to the same standard — and is not legal to sell for human use.Not approved anywhere and not in human trials. An academic research compound sold as a research chemical, typically as a powder with no pharmaceutical manufacturing behind it.
RoutesSubcutaneousOral, Subcutaneous
Half-life168 hoursNot recorded
Cheapest per mgVials only, read from vendors' own listings and dated on the price index.$1.50/mg$1.00/mg
Median per mg$6.70/mg$13.41/mg
Vendors with a price2812
Storage once mixedRefrigerated at 2–8 °C. Do not freeze. Discard if the solution is cloudy or has visible particles.A small molecule, not a peptide. Solvent choice varies, and vendors rarely say what theirs is.

Compare two other compounds · The full price index

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.